Alector, Inc. (ALEC)
| Market Cap | 213.26M -30.7% |
| Revenue (ttm) | 13.86M -82.9% |
| Net Income | -117.85M |
| EPS | -1.09 |
| Shares Out | 111.66M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,630,273 |
| Open | 1.920 |
| Previous Close | 1.880 |
| Day's Range | 1.850 - 1.950 |
| 52-Week Range | 1.090 - 3.400 |
| Beta | 0.62 |
| Analysts | Hold |
| Price Target | 3.90 (+104.19%) |
| Est. Earnings | Nov 5, 2026 |
About ALEC
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer’s disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson’s disease and Lewy body... [Read more]
Financial Performance
In 2025, Alector's revenue was $21.05 million, a decrease of -79.07% compared to the previous year's $100.56 million. Losses were -$142.93 million, 20.1% more than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for ALEC stock is "Hold." The 12-month stock price target is $3.9, which is an increase of 104.19% from the latest price.
News
Alector price target raised to $8 from $5 at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Alector (ALEC) to $8 from $5 and keeps a Buy rating on the shares. The company’s R&D day showcased…
Alector Transcript: Investor update
The strategy centers on brain-enabled biologics and nucleic acid medicines, backed by a Genentech/Roche partnership extending runway into 2029. AL137 is targeted for 2027 clinical testing; AL164 and AL062 have Q2 2028 first-in-human targets, supported by preclinical brain uptake and knockdown data.
Alector Press release: Investor update
Alector issued a press release on October 13, 2026, disclosing material business information to investors.
Alector to Host Virtual Research and Development Event Highlighting Wholly Owned Alector Brain Carrier (ABC)- Enabled Pipeline
Agenda to feature progress for AL137, its lead anti-amyloid beta antibody; AL164, its tau siRNA program; and AL062, its alpha-synuclein siRNA program
Alector price target raised to $3 from $2 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Alector (ALEC) to $3 from $2 and keeps an Underweight rating on the shares after the company announced that Genentech (RHHBY) has…
Why is Alector Stock (ALEC) 60% Higher Today?
Shares in U.S. biotech firm Alector ($ALEC) surged 60% in pre-market trading today after Swiss drugmaker Roche ($RHHBY) agreed to pay up to $1.27 billion. to license its experimental treatment…
Alector soars as Roche licenses Parkinson's therapy for up to $1.27 billion
Swiss drugmaker Roche will pay up to $1.27 billion to license Alector's experimental treatment for Parkinson's disease, the US biotech said on Monday, sending its shares surging 72% in premarket tra...
Alector enters exclusive AL050 global licensing agreement with Genentech
Alector (ALEC) announced it has entered into an exclusive global licensing agreement with Genentech, a member of Roche (RHHBY), granting Genentech worldwide rights to develop and commercialize Alector...
Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson's Disease and Other Neurodegenerative Diseases
Alector grants Genentech exclusive rights to develop and commercialize AL050, an investigational GCase Enzyme Replacement Therapy (ERT) enabled by Alector Brain Carrier (ABC), Alector's proprietary bl...
Alector Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The discussion highlighted a strategic pivot to a preclinical pipeline focused on neurodegenerative diseases, leveraging the ABC platform for brain delivery of novel therapeutics. AI and global collaborations are driving efficiency, while robust financials and strong non-human primate data support optimism for upcoming clinical milestones.
Alector Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
The company highlighted its proprietary blood-brain barrier platform and upcoming clinical entry of AL137, an anti-Aβ antibody designed for monthly subcutaneous delivery with improved safety and efficacy. Additional siRNA and enzyme programs are advancing, with partnering efforts focused on Parkinson's assets.
Alector Slides: Corporate presentation
Alector has posted slides in relation to its latest quarterly earnings report, which was published on September 10, 2026.
Alector to Participate in Upcoming Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neuro...
Alector reports Q2 EPS (21c), consensus (23c)
Reports Q2 revenue $3.32M, consensus $1.71M. “We continue to make steady progress across our ABC-enabled preclinical and research pipeline,” said Arnon Rosenthal, Chief Executive Officer of Alector (A...
Alector Reports Second Quarter 2026 Financial Results and Provides Business Update
Advancing the Alector Brain Carrier (ABC) blood-brain barrier platform across antibodies, enzymes, and siRNA, with AL137 advancing as Alector's lead ABC-enabled anti-amyloid beta (Aβ) antibody program...
Alector Quarterly report: Q2 2026
Alector has published its Q2 2026 quarterly earnings report on August 6, 2026.
Alector Earnings release: Q2 2026
Alector released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Alector Slides: Corporate presentation
Alector has posted slides in relation to its latest quarterly earnings report, which was published on August 1, 2026.
Alector and GSK partnership to end after dementia, Alzheimer's drug failures
Alector said on Wednesday that GSK had terminated their neuroscience collaboration agreement covering two experimental antibody drugs after both the drug candidates suffered clinical setbacks.
Alector reports Q1 EPS (21c), consensus (28c)
Reports Q1 revenue $1.05M, consensus $11.03M. “Over the past seven years, we have built a highly differentiated blood-brain barrier platform with the versatility to deliver antibodies, enzymes, protei...
Alector Reports First Quarter 2026 Financial Results and Provides Business Update
Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL037/AL137 (ABC-enabled antibody fo...
Alector Quarterly report: Q1 2026
Alector has published its Q1 2026 quarterly earnings report on May 7, 2026.
Alector Earnings release: Q1 2026
Alector released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Alector price target raised to $2 from 90c at Morgan Stanley
Morgan Stanley raised the firm’s price target on Alector (ALEC) to $2 from 90c and keeps an Underweight rating on the shares. AL101’s failure in the Phase 2 PROGRESS-AD trial…
Alector to discontinue PROGRESS-AD trial of nivisnebart
Alector (ALEC) confirmed that the Phase 2 PROGRESS-AD trial of nivisnebart in individuals with early Alzheimer’s disease will be discontinued. The decision follows a pre-specified futility analysis co...